Trending

#GI25

Latest posts tagged with #GI25 on Bluesky

Latest Top
Trending

Posts tagged #GI25

Preview
Atezolizumab Plus mFOLFOX6/Bevacizumab Yields PFS Benefit in First-Line dMMR/MSI-H mCRC | OncLive The addition of mFOLFOX6 and bevacizumab to atezolizumab improved PFS compared with atezolizumab monotherapy in dMMR/MSI-H mCRC.

Atezolizumab Plus mFOLFOX6/Bevacizumab Yields PFS Benefit in First-Line dMMR/MSI-H #mCRC @ascocancer.bsky.social #GI25 #oncology

www.onclive.com/view/atezoli...

0 0 0 0
Preview
Frontline Nivolumab/Ipilimumab Delivers Long-Term Efficacy in Unresectable HCC | OncLive Nivolumab plus ipilimumab continued to yield an efficacy and safety benefit vs lenvatinib or sorafenib in previously untreated, unresectable HCC.

Frontline Nivolumab/Ipilimumab Delivers Long-Term Efficacy in Unresectable #HCC @ascocancer.bsky.social #GI25 #oncology

www.onclive.com/view/frontli...

1 0 0 0
FF

FF

Lors du salon #GI25 l'industrie française a montré tout son potentiel, son attractivité et son avenir prometteur. 🚀

L'industrie d'aujourd'hui est belle, innovante, et même sexy ! Pour en savoir plus 👉 http://spkl.io/63322fQTK0

#FrenchFab #BigMédia

0 0 0 0
FF

FF

🌿 Industrie durable : ces innovations révolutionnent l'avenir !

De la transformation des déchets à des technologies responsables, découvrez 5 avancées repérées à #GI25 👉 http://spkl.io/63325ft6qt

#FrenchFab

0 0 0 0
Preview
Association Between CLDN18 and MUC1 Could Drive Novel Targeted Therapy Options in GI Cancers Aditya Shreenivas, MD, MS, discusses the association between Claudin 18 and MUC1 biomarkers and ongoing targeted therapy challenges.

Association Between CLDN18 and MUC1 Could Drive Novel Targeted Therapy Options in GI Cancers
@cityofhope.bsky.social @ascocancer.bsky.social #GI25
www.onclive.com/view/associa...

1 0 0 0
Video

"Quand on parle neutralité carbone, on parle des engrais. Quand on parle de souveraineté, on parle des engrais."

A l'occasion de Global Industrie, Thierry Blandinières revient sur la nécessité de bâtir et consolider notre souveraineté alimentaire et énergétique. A écouter !

#GI25

0 0 0 0
14H15 - Jeu, set et Match, quand l'industrie française monte sur le podium
14H15 - Jeu, set et Match, quand l'industrie française monte sur le podium YouTube video by Global Industrie

Agriculture régénératrice, carbone, compétitivité, data, engrais, innovation, revenus de l'agriculteur, souveraineté alimentaire...

En 12 minutes, Thierry Blandinières évoque les grands enjeux de l'agriculture française et européenne sur la scène de Global Industrie youtu.be/QJN8khXLfGk?... #GI25

0 0 0 0
Video

Des innovations au service de l'industrie d'aujourd'hui et de demain ?

Pour en savoir plus, rendez-vous jusqu’au vendredi 14 mars 2025 à Eurexpo Lyon !

Vidéo en collaboration commerciale avec Global Industrie

#FrenchFab #GI25 #industrie #export #industriels #Lyon #curieux #incurieuxwetrust

1 0 0 0
Mercredi 12 Mars - Grande scène - Global Industrie Lyon 2025
Mercredi 12 Mars - Grande scène - Global Industrie Lyon 2025 YouTube video by Global Industrie

"Souveraineté alimentaire et énergétique, compétitivité industrielle et rayonnement de l’offre France dans le monde"

Suivez en direct l'intervention de Thierry Blandinières, DG d'InVivo, sur la grande scène de Global Industrie 2025

🎥 www.youtube.com/watch?v=9iMM...

#GI25

0 0 0 0
Jour Bleu

Jour Bleu

Jour Bleu

Jour Bleu

Top départ pour la toute première édition de #JourBleu ! C’est tous ensemble et unis que nous lançons cette journée 100% industrie.
Rendez-vous sur la mezzanine à #GI25 📍 https://t.co/6DdwhodqzR

0 0 0 0
Preview
Pancreatic Cancer Research Highlights from ASCO GI 2025 Read about the pancreatic cancer research highlights from the ASCO GI 2025 conference, where treatments and quality-of-life were discussed.

Read about the pancreatic cancer research highlights from the ASCO GI 2025 conference, where treatments and quality-of-life were discussed. letswinpc.org/research/res...

#GI25 #OncoSky

3 0 0 0
Preview
Pancreatic Cancer Research Highlights from ASCO GI 2025 Read about the pancreatic cancer research highlights from the ASCO GI 2025 conference, where treatments and quality-of-life were discussed.

Read about the pancreatic cancer research highlights from the ASCO GI 2025 conference, where treatments and quality of life were discussed. bit.ly/3DetiaU

#GI25

1 0 0 0
Preview
Accelerating Innovation In Biliary Tract Cancer: Restructuring Treatment Models With Immunotherapy & Targeted Platforms In Advanced Disease I participated in “Accelerating Treatment Innovation in Advanced Biliary Tract Cancer ,” a CME/MOC/CE/AAPA/IPCE activity from @PeerView

Treating biliary tract cancer (BTC)? New immunotherapy & targeted therapies (eg, FGFR, IDH, and HER2) are changing the landscape. Don’t miss this OnDemand #GI25 session produced in partnership with @PeerView!

2 1 0 0
Post image

#GlobalIndustrie 2025 est de retour du 11 au 14 mars, au parc Eurexpo à #Lyon !

Ce salon #Gi25, c'est le grand rassemblement des acteurs de l'industrie et du mouvement de La #FrenchFab.

Avec une journée spéciale le 12 mars : #JourBleu !

Inscriptions ➡️ evenements.bpifrance.fr/jour-bleu-gl...

4 1 1 0
Preview
Early registration is open for ESMO GI 2025 - OncoDaily Early registration is open for ESMO GI 2025 / cancer, ESMO, ESMO GI 2025, European Society for Medical Oncology, OncoDaily, Oncology

Early registration is open for ESMO GI 2025

oncodaily.com/blog/246192

#Cancer #ESMO #GICancer #GI25 #Medicine #Health #Oncology #OncoDaily

8 0 0 0
Post image

Congratulations, Dr. Rana McKay and Dr. Justine Panian of the UCSD Moores Cancer Center, and all study collaborators, on your Trials in Progress poster highlighting the @hoosiercancer.bsky.social CANOPY study at #GI25. #OncSky

1 0 0 0
Preview
Prognostic and biological divergence of upper gastrointestinal adenocarcinomas. 350Background: Esophageal (EAC), gastroesophageal junction (GEJ) or gastric (GAC) adenocarcinoma share similar etiologies and treatment approaches. However, it is not clear if they possess similar or ...

SCI members Dean Felsher, George Fisher & others found that 3 gastrointestinal #adenocarcinomas possess substantially different OS that appears differentially associated with HER2 status, mutp53, mutKRAS and MYC amplification. bit.ly/3CBLniU #GI25

0 0 0 0
Post image

@hopkinspress.bsky.social
#GIOnc

✅Dr. Jeremy Davis from @ummedschool.bsky.social gave a very⏲️timely🗣️, fresh off the #GI25 👩‍🏫of the DRAGON-01 trial
🤔Should we consider surgery🔪(gastrectomy + cytoreduction +/- HIPEC) for a patient with metastatic gastric cancer with peritoneal carcinomatosis

2 0 1 0
Post image

Happening now: Dr. Aiwu Ruth He discusses the most compelling Liver/HCC Research from the @ASCO #GI25 meeting. Join us for this interesting discussion. bit.ly/3yFhuvr @LombardiCancer

2 0 0 0
Post image

Happening now: Dr. Reetu Mukherji discusses the most compelling Upper GI Cancer Research from the
@ASCO #GI25 meeting. Join us for this interesting discussion @georgetownlombardi.bsky.social. bit.ly/3yFhuvr

3 0 0 0
Post image

Reminder to join us tomorrow, Friday, Feb 7th, to review @ascocancer.bsky.social #GI25 research! Drs. Marshall, He, Weinberg, Noel, and Mukherji will highlight the most compelling abstracts in Colorectal, Pancreatic, Liver, and Upper GI cancers. Register today for the Zoom link: bit.ly/3yFhuvr

2 0 0 0
Post image

🔐 EXCLUSIVE CONTENT 🔐
Did you enjoy the ASCO #GI25 takeover with @shrutipatelmd.bsky.social, @cancerassassin1.bsky.social, and @shaalanbeg.bsky.social?
Get access to our exclusive GI recap story: www.onclive.com/view/case-cl...
@ascocancer.bsky.social @stanfordmedicine.bsky.social #oncology

5 2 0 0
Preview
ATG-022 Demonstrates Safety, Preliminary Efficacy in Advanced CLDN18.2+ Gastric Cancer Phase 1 study data demonstrated that ATG-022 has a manageable safety profile and produced activity in patients with gastric cancer and CLDN 18.2 expressions.

ATG-022 Demonstrates Safety, Preliminary Efficacy in Advanced CLDN18.2+ Gastric Cancer @ascocancer.bsky.social #GI25 #oncology
www.onclive.com/view/atg-022...

1 0 0 0

Case closed for #GI25 thanks to my fellows #OnlyOncologistsInTheBuilding Investigators, @shrutipatelmd.bsky.social & @shaalanbeg.bsky.social in our partnership with #OncLive. We are on the trail of more mysteries of #cancer, including unraveling causes of young-adult cancers. More to come at #ASCO25

1 0 0 0
Preview
Case Closed: Experts Piece Together the Top Takeaways From the 2025 Gastrointestinal Cancers Symposium Get the inside scoop from Drs Lou, Patel, and Beg on the top takeaways to come out of the 2025 Gastrointestinal Cancers Symposium.

🔐 EXCLUSIVE 🔐
Case Closed: Experts Piece Together the Top Takeaways From the 2025 Gastrointestinal Cancers Symposium
@cancerassassin1.bsky.social @shrutipatelmd.bsky.social @shaalanbeg.bsky.social @stanfordmedicine.bsky.social @ascocancer.bsky.social #GI25 #oncology
www.onclive.com/view/case-cl...

3 0 0 1
Preview
Diagnostic accuracy of a blood based biomarker panel for CRC detection - VJOncology Marcia Cruz-Correa, MD, PhD, University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico, comments on the potential of...

🎥Dr Marcia Cruz-Correa discusses a pilot study on a biomarker panel for early colorectal cancer detection, showing 75% accuracy and potential for improved screening:

➡️https://buff.ly/4aGasWt⬅️

#GI25 #CRCsm

1 0 0 0
Preview
ctDNA Testing May Inform Treatment, Predict Outcomes in Colorectal Cancer ctDNA testing may inform treatment decisions and predict outcomes of adjuvant chemotherapy in patients with stage II-III colorectal cancer.

www.cancertherapyadvisor.com/reports/ctdn... @ascocancer.bsky.social #GI25 @cacoloncancer.bsky.social

1 0 0 0
Preview
Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC The combination of botensilimab plus balstilimab elicited high major pathologic response rates with extended time to surgery in resectable colorectal cancer.

Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
@ascocancer.bsky.social #GI25 #crcsm #oncology #MedEd
www.onclive.com/view/neoadju...

1 0 0 0
Preview
Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCC Clinical outcomes did not significantly differ with atezolizumab plus bevacizumab vs tremelimumab and durvalumab in treatment-naive, unresectable HCC.

Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCC @ascocancer.bsky.social #GI25 #stomca www.onclive.com/view/compara...

2 1 0 0
Video

Mini photo shoot 📸

#gi25
#asco
#stomachcancer
#advocates
#signetringcell
#ddf

1 0 0 0